CDI(Clostridium Difficile Infection) : 세계 시장 전망, 역학, 경쟁 구도 시장 예측 리포트(주요 32 시장) - 2025-2035년

Global Clostridium Difficile Infection (CDI) Market Outlook

Thelansis's "Global Clostridium Difficile Infection (CDI) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report (Top 32 Markets) - 2025 To 2035" covers disease overview, epidemiology, kidney biopsy cases, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Clostridium Difficile Infection treatment modalities options for the 32 markets (North America, Europe, Middle East, Asia Pacific, Africa, South / Latin America).

Clostridium Difficile Infection Overview

Clostridioides difficile (formerly Clostridium difficile) is a Gram-positive, anaerobic, spore-forming bacillus that opportunistically colonizes the human gastrointestinal tract following the profound disruption of the normal colonic microbiota, most classically secondary to broad-spectrum antibiotic exposure. Pathogenesis is driven by the fecal-oral transmission of highly resilient spores and the subsequent elaboration of two potent exotoxins, Toxin A (enterotoxin) and Toxin B (cytotoxin)-and occasionally a binary toxin in hypervirulent strains like NAP1/BI/027-which induce severe cytoskeletal disruption, mucosal inflammation, and cellular necrosis. Clinically, C. difficile infection (CDI) ranges from self-limiting secretory diarrhea to life-threatening pseudomembranous colitis, toxic megacolon, bowel perforation, and septic shock, solidifying its status as the leading cause of healthcare-associated infective diarrhea worldwide. Because the spores are intrinsically resistant to standard antimicrobial eradication, the clinical hallmark of CDI is a notoriously high rate of disease recurrence. Consequently, the modern therapeutic paradigm has shifted dramatically; while targeted antibiotics like fidaxomicin or oral vancomycin remain the frontline standard of care for acute infection, the prevention of recurrence now heavily leverages monoclonal antibodies (such as bezlotoxumab) against Toxin B and transformative microbiome restoration therapies-including fecal microbiota transplantation (FMT) and novel, synthetic live biotherapeutic products-to reestablish colonic colonization resistance durably.

Key Highlights

• CDI represents a significant healthcare-associated infection burden in France, with the majority of cases occurring in hospitalized and elderly populations.
• Hospitalized CDI cases in France are projected to increase from 63.0K in 2025 to 65.9K by 2035, reflecting a modest growth trajectory (0.4-0.5% CAGR) driven by aging population and healthcare exposure.
• High recurrence rates (20-30%) continue to be the most critical clinical challenge, contributing to repeated hospitalizations and increased healthcare burden.
• Growing focus on recurrence prevention and microbiome restoration therapies is expected to gradually shift treatment practices beyond conventional antibiotics.

Market Overview

• The France CDI market is projected to grow from $78M in 2025 to $117M by 2035, reflecting moderate growth driven by adoption of newer therapies despite a relatively stable patient base.
• Limited patient growth (0.4-0.5% CAGR) indicates that market expansion is primarily driven by:
• Increased use of premium therapies targeting recurrence
• Gradual shift toward microbiome-based and adjunctive treatments
• Current market revenues are largely driven by standard antibiotic therapies (e.g., vancomycin, fidaxomicin), which remain the backbone of acute treatment.
• Future growth will depend on the uptake of innovative therapies focused on reducing recurrence and improving long-term outcomes, particularly in high-risk patient populations.

Market Definition:

• North America (United States, Canada)
• Europe (Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Greece, Italy, Netherlands, Norway, Poland, Portugal, Russia, Spain, Sweden, Switzerland, United Kingdom)
• Middle East (Saudi Arabia, UAE, Kuwait, Turkey)
• Asia Pacific (Australia, China, Hong Kong, India, Indonesia, Japan, Malaysia, New Zealand, Philippines, Singapore, South Korea, Taiwan, Thailand, Vietnam)
• Africa (Egypt, Nigeria, South Africa, Morocco)
• South / Latin America (Argentina, Brazil, Chile, Colombia, Mexico, Peru)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025-2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across the 32 markets (North America, Europe, Middle East, Asia Pacific, Africa, South / Latin America)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• North America (United States, Canada)
• Europe (Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Greece, Italy, Netherlands, Norway, Poland, Portugal, Russia, Spain, Sweden, Switzerland, United Kingdom)
• Middle East (Saudi Arabia, UAE, Kuwait, Turkey)
• Asia Pacific (Australia, China, Hong Kong, India, Indonesia, Japan, Malaysia, New Zealand, Philippines, Singapore, South Korea, Taiwan, Thailand, Vietnam)
• Africa (Egypt, Nigeria, South Africa, Morocco)
• South / Latin America (Argentina, Brazil, Chile, Colombia, Mexico, Peru)

Companies Mentioned

• Acurx Pharmaceuticals Inc.
• Actelion
• Lumen Bioscience, Inc.
• AstraZeneca
• Crestone, Inc
• Vedanta Biosciences, Inc.
• Gateway Pharmaceutical LLC

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets, etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key current therapies - profiles and KOL insights
• Emerging therapies
• Key takeaways
• Notable late-phase emerging therapies - profiles, launch expectations, KOL insights
• Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)